Kyowa Hakko’s Cancer Pain Drug Enters Phase III Trial
This article was originally published in PharmAsia News
Executive SummaryKyowa Hakko announced that sublingual cancer pain reliever KW-2246 entered Phase III trials in Japan. The main ingredient for KW-2246 is fentanyl. Kyowa obtained the exclusive rights to develop and market in Japan from a 2003 license agreement with Swedish company Orexo. Since this March, Kyowa has stopped marketing a cancer pain patch due to a contractual problem. (Click here for more - Japanese language)
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.